| 1. |
- Persson, Sofie, et al.
(författare)
-
Healthcare costs of dementia diseases before, during and after diagnosis : Longitudinal analysis of 17 years of Swedish register data
- 2022
-
Ingår i: Alzheimer's & Dementia. - : Wiley. - 1552-5279 .- 1552-5260. ; 18:12, s. 2560-2569
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: This study examines health-care costs attributed to dementia diseases in the 10 years prior to, during, and 6 years after diagnosis. Methods: Using administrative register data for people diagnosed with dementia (2010–2016) in southern Sweden (n = 21,184), and a comparison group without dementia, health-care costs over 17 years were examined using longitudinal regression analysis. Results: Average annual health-care costs per person were consistently higher before diagnosis in the dementia group (10 years before: Swedish krona (SEK) 2063, P <.005 and 1 year before: SEK8166, P <.005). At diagnosis, health-care costs were more than twice as high (SEK44,410, P <.005). Four to 6 years after diagnosis, there was no significant different in costs compared to comparators. Discussion: Excess health-care cost arise as early as 10 years before a formal diagnosis of dementia, and while there is a spike in cost after diagnosis, health-care costs are no different 4 years after. These findings question currently accepted assumptions on costs of dementia.
|
|
| 2. |
- Sattarov, Roman, et al.
(författare)
-
Direct Conversion of Fibroblast into Neurons for Alzheimer's Disease Research : A Systematic Review
- 2023
-
Ingår i: Journal of Alzheimer's Disease. - 1387-2877. ; 95:3, s. 805-828
-
Forskningsöversikt (refereegranskat)abstract
- Background: Alzheimer's disease (AD) is a prevalent neurodegenerative disorder without a cure. Innovative disease models, such as induced neurons (iNs), could enhance our understanding of AD mechanisms and accelerate treatment development. However, a review of AD human iN studies is necessary to consolidate knowledge. Objective: The objective of this review is to examine the current body of literature on AD human iN cells and provide an overview of the findings to date. Methods: We searched two databases for relevant studies published between 2010 and 2023, identifying nine studies meeting our criteria. Results: Reviewed studies indicate the feasibility of generating iNs directly from AD patients' fibroblasts using chemical induction or viral vectors. These cells express mature neuronal markers, including MAP-2, NeuN, synapsin, and tau. However, most studies were limited in sample size and primarily focused on autosomal dominant familial AD (FAD) rather than the more common sporadic forms of AD. Several studies indicated that iNs derived from FAD fibroblasts exhibited abnormal amyloid-β metabolism, a characteristic feature of AD in humans. Additionally, elevated levels of hyperphosphorylated tau, another hallmark of AD, were reported in some studies. Conclusion: Although only a limited number of small-scale studies are currently available, AD patient-derived iNs hold promise as a valuable model for investigating AD pathogenesis. Future research should aim to conduct larger studies, particularly focusing on sporadic AD cases, to enhance the clinical relevance of the findings for the broader AD patient population. Moreover, these cells can be utilized in screening potential novel treatments for AD.
|
|
